Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 10/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18023562 | 1.00 | CTSC (0.55) | CTSCCTSKCTSSCYP2C19RAB9A | |
| SCHEMBL487474 | 0.84 | CTSK (0.53) | CTSCCTSKCTSSCYP2C19RAB9A | |
| SCHEMBL2058609 | 0.83 | CTSC (0.59) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| SCHEMBL1631750 | 0.83 | CTSC (0.59) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| SCHEMBL19699149 | 0.83 | CTSC (0.59) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| Hydrochloric Acid SCHEMBL7066923 | 0.82 | CTSC (0.58) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| Hydrochloric Acid SCHEMBL28362983 | 0.82 | CTSC (0.58) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| SCHEMBL20543720 | 0.82 | CTSC (0.55) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| Hydrochloric Acid SCHEMBL2524346 | 0.82 | CTSC (0.58) | CTSCCTSSCYP2C19RAB9ASLC1A3 | |
| Hydrochloric Acid SCHEMBL29780783 | 0.81 | CTSC (0.53) | CTSCCTSSCYP2C19RAB9ASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177890-A1 | LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-06-28 | — | — | US | disclosed |
| EP-3251698-A1 | LIGAND-CYTOTOXICITY DRUG CONJUGATE, PREPARING METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177890-A1 | LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF | LDLR, SELPLG, FOLR1 | CTSC 1847/4885CTSK 2128/4885CTSS 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.